The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Open accessAbstract
The Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program issued an evidence-based set of guidelines on cholesterol management in 2001. Since the publication of ATP III, 5 major clinical trials of statin therapy with clinical end points have been published. These trials addressed issues that were not examined in previous clinical trials of cholesterol-lowering therapy. The present document reviews the results of these recent trials and assesses their implications for cholesterol management. Therapeutic lifestyle changes (TLC) remain an essential modality in clinical management. The trials confirm the benefit of cholesterol-lowering therapy in high-risk patients and support the ATP III treatment goal of low-density lipoprotein cholesterol (LDL-C) <100 mg/dL. They support the inclusion of patients with diabetes in the high-risk category and confirm the benefits of LDL-lowering therapy in these patients. They further confirm that older persons benefit from therapeutic lowering of LDL-C. The major recommendations for modifications to footnote the ATP III treatment algorithm are the following. In high-risk persons, the recommended LDL-C goal is <100 mg/dL, but when risk is very high, an LDL-C goal of <70 mg/dL is a therapeutic option, ie, a reasonable clinical strategy, on the basis of available clinical trial evidence. This therapeutic option extends also to patients at very high risk who have a baseline LDL-C <100 mg/dL. Moreover, when a high-risk patient has high triglycerides or low high-density lipoprotein cholesterol (HDL-C), consideration can be given to combining a fibrate or nicotinic acid with an LDL-lowering drug. For moderately high-risk persons (2+ risk factors and 10-year risk 10% to 20%), the recommended LDL-C goal is <130 mg/dL, but an LDL-C goal <100 mg/dL is a therapeutic option on the basis of recent trial evidence. The latter option extends also to moderately high-risk persons with a baseline LDL-C of 100 to 129 mg/dL. When LDL-lowering drug therapy is employed in high-risk or moderately high-risk persons, it is advised that intensity of therapy be sufficient to achieve at least a 30% to 40% reduction in LDL-C levels. Moreover, any person at high risk or moderately high risk who has lifestyle-related risk factors (eg, obesity, physical inactivity, elevated triglycerides, low HDL-C, or metabolic syndrome) is a candidate for TLC to modify these risk factors regardless of LDL-C level. Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cutpoints of therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of combination fibrate–statin therapy in such patients is consistent with current guidelines that recommend treatment for patients with hypertriglyceridemia and low HDL cholesterol levels that persist despite statin therapy.25”
From Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus (2010) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“According to practice guidelines in place at the time of patient enrollment in IMPROVE-IT, treatment of hypercholesterolemia was based on lowering LDL cholesterol to target levels, 20,21 which were set on the basis of a patient's risk of cardiovascular events.”
From Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (2015) · cites this paper as [20]
In the citing paper
“Statins are currently the most effective agents available for managing dyslipidemia and have been shown to reduce CV events in a wide variety of patient populations [10,25,31].”
In the citing paper
“Statins are currently the most effective agents available for managing dyslipidemia and have been shown to reduce CV events in a wide variety of patient populations [10,25,31].”
In the citing paper
“Assiduous attention to abnormalities other than hyperglycemia that accompany type 2 diabetes, such as hypertension and dyslipidaemia, has been shown to improve microvascular and cardiovascular complications.”
From Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009) · cites this paper as [21]
In the citing paper
“Nevertheless, measurement and treatment of blood lipids, blood pressure, and glucose levels have became the major emphases for cardiovascular risk reduction.”
From Beyond Established and Novel Risk Factors: Lifestyle Risk Factors for Cardiovascular Disease (2008) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Self-citationExpert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Self-citationOLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401
Self-citation
Cited by
Sorted by citations
Items 401–500 of 1,060
How do we improve patient compliance and adherence to long-term statin therapy?
Maningat, P., Gordon, B. R., & Breslow, J. L. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0291-7 · Cited by 208
Owens, D. S., Katz, R., Takasu, J., Kronmal, R. A., Budoff, M. J., & O’Brien, K. D. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.10.071 · Cited by 211
Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy
Silva, M. J., Matthews, M. L., Jarvis, C. I., Nolan, N. M., Belliveau, P., Malloy, M., & Gandhi, P. J. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.02.008 · Cited by 207
Mancia, G., Messerli, F. H., Bakris, G. L., Zhou, Q., Champion, A., & Pepine, C. J. (2007) · Hypertension · doi:10.1161/hypertensionaha.107.090290 · Cited by 207
Cardiovascular disease in chronic kidney disease: untying the Gordian knot
Hajhosseiny, R., Khavandi, K., & Goldsmith, D. J. A. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02954.x · Cited by 208
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
Schmidt, A. F., Pearce, L. S., Wilkins, J. T., Overington, J. P., Hingorani, A. D., & Casas, J. P. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011748.pub2 · Cited by 203
Statin‐Associated Adverse Cognitive Effects: Survey Results from 171 Patients
Evans, M. A., & Golomb, B. A. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.7.800 · Cited by 209
Hert, M. A. F. D., van Winkel, R., Eyck, D. V., Hanssens, L. S., Wampers, M., Scheen, A. J., & Peuskens, J. (2006) · Clinical Practice and Epidemiology in Mental Health · doi:10.1186/1745-0179-2-14 · Cited by 209
Lowering LDL—not only how low, but how long?
Brown, M. S., & Goldstein, J. L. (2006) · Science · doi:10.1126/science.1125884 · Cited by 204
Socioeconomic and Ethnic Disparities in Cardiovascular Risk In the United States, 2001–2006
Karlamangla, A. S., Merkin, S. S., Crimmins, E. M., & Seeman, T. E. (2010) · Annals of Epidemiology · doi:10.1016/j.annepidem.2010.05.003 · Cited by 209
Kühnast, S., van der Hoorn, J. W. A., Pieterman, E. J., van den Hoek, A. M., Sasiela, W. J., Gusarova, V., Peyman, A., Schäfer, H.-L., Schwahn, U., Jukema, J. W., et al. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m051326 · Cited by 204
CYP3A4*22: Promising Newly IdentifiedCYP3A4Variant Allele for Personalizing Pharmacotherapy
Elens, L., van Gelder, T., Hesselink, D. A., Haufroid, V., & van Schaik, R. H. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.187 · Cited by 205
Sabatine, M. S., Wiviott, S. D., Im, K., Murphy, S. A., & Giugliano, R. P. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.2258 · Cited by 214
Steinberg, D. H. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r600009-jlr200 · Cited by 205
Hypertriglyceridemia secondary to obesity and diabetes
Subramanian, S., & Chait, A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.003 · Cited by 205
Martinez, R. C. R., Bedani, R., & Saad, S. M. I. (2015) · British Journal Of Nutrition · doi:10.1017/s0007114515003864 · Cited by 217
The Effect of Hypercholesterolemia on Rotator Cuff Disease
Abboud, J. A., & Kim, J. S. (2009) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-009-1151-9 · Cited by 200
The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials
Josan, K., Majumdar, S. R., & McAlister, F. A. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.070675 · Cited by 197
Koh, K. K., Quon, M. J., Han, S. H., Chung, W., Ahn, J. Y., Seo, Y., Choi, I. S., & Shin, E. K. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.02.052 · Cited by 199
Cardiovascular Disease Under the Influence of Excess Visceral Fat
Després, J. (2007) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0b013e318057d4c9 · Cited by 205
Ballantyne, C. M., Weiss, R., Moccetti, T., Vogt, A., Eber, B., Sosef, F., & Duffield, E. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.10.022 · Cited by 196
Levine, G. N., D'Amico, A. V., Berger, P., Clark, P. E., Eckel, R. H., Keating, N. L., Milani, R. V., Sagalowsky, A. I., Smith, M. R., Zakai, N., et al. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20061 · Cited by 188
The long-term renal and cardiovascular consequences of prematurity
Abitbol, C. L., & Rodriguez, M. M. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.38 · Cited by 194
Ford, E. S., Greenwald, J. H., Richterman, A. G., Rupert, A. W., Dutcher, L. S., Badralmaa, Y., Natarajan, V., Rehm, C. A., Hadigan, C. M., & Sereti, I. (2010) · AIDS · doi:10.1097/qad.0b013e32833ad914 · Cited by 195
Musa-Veloso, K., Poon, T. H., Elliot, J. A., & Chung, C. (2011) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2011.02.001 · Cited by 195
Ataie‐Jafari, A., Larijani, B. A., Majd, H. A., & Tahbaz, F. (2009) · Annals of Nutrition and Metabolism · doi:10.1159/000203284 · Cited by 194
Rosenzweig, J. L., Ferrannini, E., Grundy, S. M., Haffner, S. M., Heine, R. J., Horton, E. S., & Kawamori, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0222 · Cited by 197
Self-citationFunctional Role of Phosphodiesterase 3 in Cardiomyocyte Apoptosis
Ding, B., Abe, J., Wei, H., Huang, Q., Walsh, R. A., Molina, C. A. F., Zhao, A. Z., Sadoshima, J., Blaxall, B. C., Berk, B. C., et al. (2005) · Circulation · doi:10.1161/01.cir.0000165128.39715.87 · Cited by 197
Presence of Coronary Plaques in Patients with Nonalcoholic Fatty Liver Disease
Assy, N., Djibre, A., Farah, R. E., Grosovski, M., & Marmor, A. T. (2010) · Radiology · doi:10.1148/radiol.09090769 · Cited by 194
2018 Guidelines for the Management of Dyslipidemia in Korea
Rhee, E., Kim, H. C., Kim, J. H., Lee, E. Y., Kim, B. J., Kim, E. M., Song, Y., Lim, J. H., Kim, B. J., Choi, S., et al. (2019) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2019.8.2.78 · Cited by 194
Westin, G. G., Armstrong, E. J., Bang, H., Yeo, K.-K., Anderson, D., Dawson, D. L., Pevec, W. C., Amsterdam, E. A., & Laird, J. R. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.073 · Cited by 189
Jones, M. L., Tomaro-Duchesneau, C., Martoni, C. J., & Prakash, S. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.758706 · Cited by 190
Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy
Chatzizisis, Y. S., Koskinas, K. C., Misirli, G., Vaklavas, C., Hatzitolios, A. I., & Giannoglou, G. D. (2010) · Drug Safety · doi:10.2165/11319380-000000000-00000 · Cited by 187
Comparing Impact and Cost-Effectiveness of Primary Prevention Strategies for Lipid-Lowering
Pletcher, M. J., Lazar, L., Bibbins-Domingo, K. B., Moran, A., Rodondi, N., Coxson, P. G., Lightwood, J., Williams, L., & Goldman, L. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-4-200902170-00005 · Cited by 187
New Drugs for the Treatment of Diabetes
Inzucchi, S. E., & McGuire, D. K. (2008) · Circulation · doi:10.1161/circulationaha.107.735795 · Cited by 188
Long-term survival in patients with refractory angina
Henry, T. D., Satran, D., Hodges, J. S., Johnson, R. K., Poulose, A. K., Campbell, A. R., Garberich, R., Bart, B. A., Olson, R. E., Boisjolie, C. R., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht165 · Cited by 188
ACC/AHA 2004 guideline update for coronary artery bypass graft surgery
the American Association for Thoracic Surgery, & the Society of Thoracic Surgeons (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.08.002 · Cited by 187
Gaba, P., O’Donoghue, M. L., Park, J., Wiviott, S. D., Atar, D., Kuder, J., Im, K., Murphy, S. A., Ferrari, G. M. D., Gaciong, Z. A., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.063399 · Cited by 188
Elam, M. B., Ginsberg, H. N., Lovato, L. C., Corson, M., Largay, J., Leiter, L. A., Lopez, C., O’Connor, P. J., Sweeney, M. E., Weiss, D., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4828 · Cited by 185
Cardiovascular drug therapy in the elderly: benefits and challenges
Fleg, J. L., Aronow, W. S., & Frishman, W. H. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.162 · Cited by 186
The Current State of Niacin in Cardiovascular Disease Prevention
Lavigne, P. M., & Karas, R. H. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.10.030 · Cited by 185
Feig, J. E., Pineda‐Torra, I., Sanson, M., Bradley, M. N., Vengrenyuk, Y., Bogunovic, D., Gautier, E. L., Rubinstein, D., Hong, C., Liu, J., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci38911 · Cited by 191
Jenkins, D. J., Kendall, C. W., Faulkner, D. A., Nguyen, T., Kemp, T., Marchie, A., Wong, J. M., de Souza, R., Emam, A., Vidgen, E., et al. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn.83.3.582 · Cited by 184
Sood, N. A., Baker, W. L., & Coleman, C. I. (2008) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/88.4.1167 · Cited by 184
Decision Making in Medicine and Health Care
Kaplan, R. M., & Frosch, D. L. (2004) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.1.102803.144118 · Cited by 186
Sloan‐Lancaster, J., Abu-Raddad, E., Polzer, J. P., Miller, J. W., Scherer, J. C., Gaetano, A. D., Berg, J. K., & Landschulz, W. H. (2013) · Diabetes Care · doi:10.2337/dc12-1835 · Cited by 187
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.185752 · Cited by 185
Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors
Howard, B. V., Best, L. G., Galloway, J. M., Howard, W. J., Jones, K., Lee, E. T., Ratner, R. E., Resnick, H. E., & Devereux, R. B. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1299 · Cited by 180
Shimizu, M., Hashiguchi, M., Shiga, T., Tamura, H.-O., & Mochizuki, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139795 · Cited by 182
Sahebkar, A., & Watts, G. F. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.06.019 · Cited by 181
Monocytes as Regulators of Inflammation and HIV-Related Comorbidities during cART
Anzinger, J. J., Butterfield, T. R., Angelovich, T. A., Crowe, S. M., & Palmer, C. S. (2014) · Journal of Immunology Research · doi:10.1155/2014/569819 · Cited by 185
Ghandehari, H., Kamal-Bahl, S., & Wong, N. D. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.03.005 · Cited by 180
Bays, H. E., Ose, L., Fraser, N., Tribble, D. L., Quinto, K., Reyes, R., Johnson‐Levonas, A. O., Sapre, A., & Donahue, S. R. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.11.016 · Cited by 178
Akdim, F., Visser, M. E., Tribble, D. L., Baker, B. F., Stroes, E. S. G., Yu, R. Z., Flaim, J., Su, J. Q., Stein, E. A., & Kastelein, J. J. P. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.01.003 · Cited by 175
Pleiotropic effects of statins: new therapeutic targets in drug design
Bedi, O., Dhawan, V., Sharma, P. L., & Kumar, P. (2016) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-016-1252-4 · Cited by 186
Nasir, K., Michos, E. D., Blumenthal, R. S., & Raggi, P. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.07.052 · Cited by 177
Ballantyne, C. M., Davidson, M. H., MacDougall, D. E., Bays, H. E., DiCarlo, L. A., Rosenberg, N. L., Margulies, J., & Newton, R. S. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.050 · Cited by 175
Sahebkar, A., & Watts, G. F. (2013) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-013-6479-4 · Cited by 176
Reducing the Health Risks of Diabetes
Williams, G. C., Patrick, H., Niemiec, C. P., Williams, L. K., Divine, G., Lafata, J. E., Heisler, M., Tunceli, K., & Pladevall, M. (2009) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721709333856 · Cited by 195
Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience
Mampuya, W. M., Frid, D., Rocco, M., Huang, J., Brennan, D. M., Hazen, S. L., & Cho, L. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.06.004 · Cited by 173
McKeage, K., & Keating, G. M. (2011) · Drugs · doi:10.2165/11208090-000000000-00000 · Cited by 181
Bayturan, O., Kapadia, S., Nicholls, S. J., Tuzcu, E. M., Shao, M., Uno, K., Shreevatsa, A., Lavoie, A. J., Wolski, K., Schoenhagen, P., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.050 · Cited by 174
Cost-Effectiveness of Statin Therapy for Primary Prevention in a Low-Cost Statin Era
Lazar, L. D., Pletcher, M. J., Coxson, P. G., Bibbins-Domingo, K. B., & Goldman, L. (2011) · Circulation · doi:10.1161/circulationaha.110.986349 · Cited by 176
Nonsurgical Management of Obesity in Adults
Eckel, R. H. (2008) · New England Journal of Medicine · doi:10.1056/nejmcp0801652 · Cited by 173
The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes
Meerwaldt, R., Links, T. P., Zeebregts, C. J., Tio, R. A., Hillebrands, J., & Smit, A. J. (2008) · Cardiovascular Diabetology · doi:10.1186/1475-2840-7-29 · Cited by 172
Risk factor status and vascular events in patients with symptomatic intracranial stenosis
Chaturvedi, S., Turan, T. N., Lynn, M., Kasner, S. E., Romano, J. G., Cotsonis, G., Frankel, M., & Chimowitz, M. I. (2007) · Neurology · doi:10.1212/01.wnl.0000279338.18776.26 · Cited by 173
Nichols, G. A., & Koro, C. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.08.022 · Cited by 173
Lipid-lowering agents that cause drug-induced hepatotoxicity.
Bhardwaj, S. S., & Chalasani, N. (2007) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.06.010 · Cited by 173
Murphy, S. A., Cannon, C. P., Wiviott, S. D., McCabe, C. H., & Braunwald, E. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.005 · Cited by 175
Daniels, S. R., Gidding, S. S., & de Ferranti, S. D. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.03.453 · Cited by 173
Dong, H., Zhao, Y., Zhao, L., & Lu, F. (2013) · Planta Medica · doi:10.1055/s-0032-1328321 · Cited by 171
Grenon, S. M., Vittinghoff, E., Owens, C. D., Conte, M. S., Whooley, M., & Cohen, B. E. (2013) · Vascular Medicine · doi:10.1177/1358863x13493825 · Cited by 169
Formation of Dysfunctional High-Density Lipoprotein by Myeloperoxidase
Nicholls, S. J., Zheng, L., & Hazen, S. L. (2005) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2005.06.004 · Cited by 171
Iakoubova, O. A., Tong, C. H., Rowland, C. M., Kirchgessner, T. G., Young, B. A., Arellano, A. R., Shiffman, D., Sabatine, M. S., Campos, H., Packard, C. J., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.05.057 · Cited by 170
Gutierrez, M. J., Rosenberg, N. L., MacDougall, D. E., Hanselman, J. C., Margulies, J. R., Strange, P., Milad, M. A., McBride, S. J., & Newton, R. S. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302677 · Cited by 170
Coronary Heart Disease in Patients With Diabetes
Berry, C., Tardif, J., & Bourassa, M. G. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.046 · Cited by 170
Effects of Early Treatment With Statins on Short-term Clinical Outcomes in Acute Coronary Syndromes
Briel, M., Schwartz, G. G., Thompson, P. L., de Lemos, J. A., Blazing, M. A., van Es, G., Kayıkçıoğlu, M., Arntz, H.-R., den Hartog, F. R., Veeger, N. J. G. M., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2046 · Cited by 169
Keating, G. M., & Croom, K. F. (2007) · Drugs · doi:10.2165/00003495-200767010-00013 · Cited by 169
An assessment by the Statin Intolerance Panel: 2014 update
Guyton, J. R., Bays, H. E., Grundy, S. M., & Jacobson, T. A. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.03.002 · Cited by 165
Self-citationImportance of cardiovascular disease risk management in patients with type 2 diabetes mellitus
Lorber, D. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s61438 · Cited by 171
Where are we with probucol: A new life for an old drug?
Yamashita, S., & Matsuzawa, Y. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.04.002 · Cited by 171
Safety of Aggressive Lipid Management
Davidson, M. H., & Robinson, J. G. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.01.067 · Cited by 166
Statins in Familial Hypercholesterolemia
Besseling, J., Hovingh, G. K., Huijgen, R., Kastelein, J. J. P., & Hutten, B. A. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.04.054 · Cited by 178
Berthold, H. K., Unverdorben, S., Degenhardt, R., Bulitta, M., & Gouni‐Berthold, I. (2006) · JAMA · doi:10.1001/jama.295.19.2262 · Cited by 170
The Safety of Rosuvastatin as Used in Common Clinical Practice
Alsheikh-Ali, A. A. A., Ambrose, M. S., Kuvin, J. T., & Karas, R. H. (2005) · Circulation · doi:10.1161/circulationaha.105.555482 · Cited by 166
Linsel‐Nitschke, P., Götz, A., Erdmann, J., Brænne, I., Braund, P. S., Hengstenberg, C., Stark, K. J., Fischer, M., Schreiber, S., Mokhtari, N. E. E., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002986 · Cited by 168
Obesity and Atherogenic Dyslipidemia
Bamba, V., & Rader, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.056 · Cited by 166
Lipid Profiles in Patients with Rheumatoid Arthritis: Mechanisms and the Impact of Treatment
Steiner, G. A., & Urowitz, M. B. (2008) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.01.015 · Cited by 168
2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary
Levine, G. N., Bates, E., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., Hollenberg, S. M., et al. (2012) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.23438 · Cited by 168
Recent advances in pharmacotherapy for hypertriglyceridemia
Sahebkar, A., Chew, G. T., & Watts, G. F. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2014.07.002 · Cited by 166
Lloyd‐Jones, D. M., Huffman, M. D., Karmali, K. N., Sanghavi, D. M., Wright, J. S., Pelser, C. B., Gulati, M., Masoudi, F. A., & Goff, D. C. (2016) · Circulation · doi:10.1161/cir.0000000000000467 · Cited by 167
Cholesterol negatively regulates IL-9–producing CD8+ T cell differentiation and antitumor activity
Ma, X., Bi, E., Huang, C., Lu, Y., Xue, G., Guo, X., Wang, A., Yang, M., Qian, J., Dong, C., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20171576 · Cited by 167
Calderon, R. M., Cubeddu, L. X., Goldberg, R. B., & Schiff, E. R. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0365 · Cited by 164
Human cholesterol metabolism and therapeutic molecules
Charlton-Menys, V., & Durrington, P. N. (2007) · Experimental Physiology · doi:10.1113/expphysiol.2007.035147 · Cited by 167
Markers of inflammation and their clinical significance
Ballantyne, C. M., & Nambi, V. (2005) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2005.02.005 · Cited by 168
Hayward, R. A., Hofer, T. P., & Vijan, S. S. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-7-200610030-00010 · Cited by 163
AJC Editor's Consensus: Psoriasis and Coronary Artery Disease
Friedewald, V. E., Cather, J. C., Gelfand, J. M., Gordon, K. B., Gibbons, G. H., Grundy, S. M., Jarratt, M., Krueger, J. G., Ridker, P. M., Stone, N. J., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.004 · Cited by 163
Self-citationBrain Cholesterol Synthesis in Mice Is Affected by High Dose of Simvastatin but Not of Pravastatin
Thelen, K., Rentsch, K., Gutteck, U., Heverin, M., Olin, M., Andersson, U., von Eckardstein, A., Björkhem, I., & Lütjohann, D. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.094136 · Cited by 163
Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome
Vignozzi, L., Gacci, M., & Maggi, M. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2015.301 · Cited by 165
Lee, W., Peng, L., Chiou, S.-T., & Chen, L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160876 · Cited by 163
Metadata
- Authors
- Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J.
- Affiliations
- American College of Cardiology (US)
- Venue
- Circulation
- Published
- 2004-07-13
- Volume
- 110
- Issue
- 2
- Pages
- 227-239
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2106343349
- Cited by
- 6,902
- References
- 54
- Citations by year
- 2026: 32 · 2025: 44 · 2024: 72 · 2023: 71 · 2022: 85 · 2021: 100 · 2020: 127 · 2019: 137 · 2018: 152 · 2017: 189 · 2016: 248 · 2015: 324 · 2014: 382 · 2013: 506 · 2012: 489
- FWCI
- 539.21
- Type
- journal article
- Language
- en
- Update notices
- correction (2004-08-10)
- Open access
- bronze
- doi.org
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- American Heart Association
- American College of Cardiology Foundation
- National Heart, Lung, and Blood Institute
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- Adult Treatment Panel III, LDL cholesterol targets, statin therapy, cholesterol-lowering therapy, diabetes mellitus, older adults, triglycerides, HDL cholesterol, nicotinic acid, therapeutic lifestyle changes, cardiovascular risk stratification, hypercholesterolemia, metabolic syndrome, cardiovascular disease prevention
- MeSH terms
- Aged, Anticholesteremic Agents, Antihypertensive Agents, Hypolipidemic Agents, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Humans, Hypercholesterolemia, Hypertension, Cholesterol, LDL, Middle Aged, Myocardial Infarction, Patient Education as Topic, Risk, Risk Factors, Comorbidity, Thrombolytic Therapy, Randomized Controlled Trials as Topic, Practice Guidelines as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
